Stifel Maintains Buy on RxSight, Raises Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Thomas Stephan has maintained a Buy rating on RxSight (NASDAQ:RXST) and increased the price target from $54 to $64. This adjustment reflects a positive outlook on RxSight's stock performance.
February 29, 2024 | 5:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Thomas Stephan reaffirms a Buy rating on RxSight and raises the price target to $64, indicating a positive outlook.
The increase in price target by a reputable analyst suggests a strong confidence in RxSight's future performance. This is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100